Cyclopharm : 18-Oct-2017 – Cyclopharm CEO Presentation at Australian MicroCap Conference (678.12KB)

Cyclopharm Limited‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌

A profitable and growing market leader in nuclear lung imaging

1

Cyclopharm Limited (CYC) is a leading diagnostic lung imaging company

• A world leader in functional lung ventilation imaging technology

• Recurring consumables and capital equipment revenue streams

• A profitable and growing company with a history of dividend payments

• Lead nuclear medicine product Technegas is currently available in 56 countries with significant opportunity to expand into USA with FDA trial completion expected in Q3 2018

• Opportunity to broaden Technegas applications beyond pulmonary embolism diagnosis into large addressable markets such as COPD and Asthma

  Share Price (as at 17 October 17)	$0.84
  Shares on Issue	68.3 million
  Market Capitalisation	$57 million
  Cash (30 Jun 17)	$10.6 million

  2

  CYC has clear strategy to leverage our position as a leading player in the global nuclear medicine imaging market and lung health space to expand the use of our proprietary products and introduce new innovative technology.

  We will do this by:

• Attaining approval to distribute Technegas in the USA

• Expanding the use of Technegas beyond the traditional diagnosis of Pulmonary Embolism into significantly larger applications such as COPD1 and Asthma, Lung Cancer and Pulmonary Hypertension for both diagnosis and patient management.

• Identifying, developing and commercialising complementary innovative technology such as UltraluteTM

• Leveraging our core global regulatory strengths, fiscal discipline, strong balance sheet and well developed expertise in nuclear medicine and pulmonary healthcare to seek out complementary technologies and businesses

• COPD-Chronic Obstructive Pulmonary Disease 3

• Group Sales Revenue $6.06 million
• Gross Margin $5.00 million
• Net Loss After Tax ($1.43) million
• Interim Dividend 0.5 cents per share
• Underlying Technegas EBITDA1 $861,000
• FDA Trial expenses ($1.58) million
• Strong balance sheet $10.62 million of cash reserves
• Guidance Affirmed Excluding the positive impact of the large Chinese order in FY16, the Board expects continuing modest growth in underlying Technegas volumes for FY17

Note 1: Underlying Results represent results from the division excluding realised and unrealised foreign exchange gains and losses and FDA Expenses

4